We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hvivo Plc | LSE:HVO | London | Ordinary Share | GB00B9275X97 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.75 | 2.75% | 28.00 | 27.60 | 28.00 | 27.80 | 27.25 | 27.25 | 1,993,935 | 16:35:24 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 56.04M | 16.12M | 0.0237 | 11.73 | 185.4M |
From Jul 2019 to Jul 2024
TIDMHVO
RNS Number : 9421L
hVIVO plc
30 April 2015
For immediate release: 30 April 2015
HVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, was notified today that on 23 April 2015, Jim Winschel, a Non-Executive Director of the Company, purchased 12,350 Ordinary Shares of 5 pence each in the Company ("Ordinary Shares") at a price of 330 pence per share.
Following this transaction, Mr Winschel's total interest in the Company has increased by 12,350 Ordinary Shares to a total of 15,702 Ordinary Shares, representing approximately 0.02% of the Company's issued share capital.
For further information please contact:
hVIVO plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Media Enquiries +44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSWGUAPCUPAGMU
1 Year Hvivo Chart |
1 Month Hvivo Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
